AQP9 and metabolic dysfunction-associated steatotic liver disease: Figure 3 reports the interplay between liver AQP9 and adipose AQP3 and AQP7 in NAFLD states associated with obesity and T2D. The potential selective modulation of aquaglyceroporins and caveolins in liver and other metabolic organs in the therapy of NAFLD and other severe metabolic disease would also be worth further investigation [46].